{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.6","value":"144"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Cmax was defined as the maximum observed plasma concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with recurrent, advanced locoregional disease or distant metastatic disease who did not receive any prior chemotherapy received retifanlimab 500 mg, administered by IV infusion over 60 minutes on Day 1 Q4W.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) Evaluable Population: all participants who received at least 1 dose of study drug and have provided a Baseline and at least 1 post-dose PK sample","reportingStatus":"POSTED","timeFrame":"preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1","title":"First-dose Cmax of Retifanlimab","type":"SECONDARY","unitOfMeasure":"micrograms per milliliter (μg/mL)"}